Hydroxyurea

Hydroxyurea is an antineoplastic agent that inhibits DNA replication and cell proliferation and induces cell cycle arrest in the G1/S phase. It inhibits proliferation of NCI H460 human lung cancer cells in vitro (IC50 = 0.56 mM). Hydroxyurea reduces ribonucleoside diphosphate reductase (RNR) activity by 75% when used at a concentration of 5 mM via degradation of its active site tyrosyl radical. In a humanized mouse model of sickle cell disease (SCD), it reduces leukocyte adhesion and extravasation via NO production and a cGMP-dependent pathway. Hydroxyurea also inhibits HIV-1 viral replication in peripheral blood mononuclear cells (PBMCs) in a dose-dependent manner with an IC90 value of 0.4 mM. Formulations containing hydroxyurea have been used to treat cancer, SCD, and psoriasis.Formal Name: N-hydroxy-urea. CAS Number: 127-07-1. Synonyms: NCI C04831, NSC 32065. Molecular Formula: CH4N2O2. Formula Weight: 76.1. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 1 mg/ml, DMSO: 1 mg/ml, Water: 10 mg/ml. SMILES: NC(NO)=O. InChi Code: InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4). InChi Key: VSNHCAURESNICA-UHFFFAOYSA-N.